Business Context and Reporting Period
This Form 8-K Current Report was filed by Inogen, Inc. on March 22, 2022. The filing addresses significant changes to the composition of the Company's Board of Directors, including the resignation of three directors and the appointment of three new directors, effective March 22, 2022.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance changes and director compensation arrangements.
Material Changes
- Resignations: Benjamin M. Anderson-Ray, Heath Lukatch, Ph.D., and Loren McFarland resigned from the Board of Directors and all associated committees. The filing states these resignations were not the result of any disagreement with the Company regarding operations, policies, or practices.
- Appointments: Kevin King, Mary Kay Ladone, and Glenn Boehnlein were appointed to the Board.
- Committee Assignments:
- Audit Committee: Glenn Boehnlein (Chair), Kevin King, and Mary Kay Ladone.
- Compensation Committee: Kevin King (Chair), Heather Rider, and Mary Kay Ladone.
- Nominating Committee: Heather Rider (Chair), Kristen Miranda, and Elizabeth Mora.
- Compliance Committee: Elizabeth Mora (Chair) and Kristen Miranda.
Guidance, Outlook, and Compensation
The filing details the compensation structure for the newly appointed directors under the Company's outside director compensation policy:
- Kevin King: $45,000 annual board fee, $10,000 for Audit Committee service, and $15,000 for chairing the Compensation Committee.
- Mary Kay Ladone: $45,000 annual board fee, $10,000 for Audit Committee service, and $7,500 for Compensation Committee service.
- Glenn Boehnlein: $45,000 annual board fee and $20,000 for chairing the Audit Committee.
- Equity Awards: Each new director received an initial award of 459 restricted stock units (RSUs), vesting on the earlier of May 10, 2022, or the day prior to the 2022 annual meeting of stockholders.
The filing includes a Regulation FD disclosure referencing a press release issued on March 23, 2022, regarding these appointments. No forward-looking financial guidance or risk factors specific to the Company's operations were disclosed in this document.
Investor Verification Checklist
- Verify the professional backgrounds of the new directors (King, Ladone, Boehnlein) to assess their specific expertise in medical technology and finance.
- Confirm the total number of board seats and the timeline for the 2022 annual meeting of stockholders to understand the term expiration dates for Class II and Class III directors.
- Review the Company's 2014 Equity Incentive Plan to understand the broader context of the RSU awards granted to the new directors.
- Check for any subsequent filings that may provide financial results or strategic updates following this governance transition.